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Naringenin Promotes Thermogenic Gene Expression  
in Human White Adipose Tissue
Candida J. Rebello1, Frank L. Greenway1 , Frank H. Lau2, Yuan Lin2, Jacqueline M. Stephens1 ,  
William D. Johnson1, and Ann A. Coulter1
Objective: Naringenin, a citrus flavonoid, prevents diet-induced weight gain and improves glucose and lipid 
metabolism in rodents. There is evidence that naringenin activates brown fat and increases energy expendi-
ture in mice, but little is known about its effects in humans. The goal of this study was to examine the effects 
of naringenin on energy expenditure in adipose tissue.
Methods: Human white adipocyte cultures (hADSC) and abdominal subcutaneous adipose tissue (pWAT) 
were treated with naringenin for 7 to 14 days. Expression (quantitative real-time polymerase chain reaction, 
immunoblotting) of candidate genes involved in thermogenesis and glucose metabolism was measured. 
Oxygen consumption rate was measured in hADSC using a Seahorse flux analyzer.
Results: In hADSC, naringenin increased expression of the genes associated with thermogenesis and fat 
oxidation, including uncoupling protein 1 and adipose triglyceride lipase, and key factors associated with 
insulin sensitivity, including glucose transporter type 4, adiponectin, and carbohydrate-responsive element-
binding  protein (P < 0.01). Similar responses were observed in pWAT. Basal, ATP-linked, maximal and 
reserve oxygen consumption rate increased in the naringenin-treated hADSC (P < 0.01).
Conclusions: Naringenin increases energy expenditure in hADSC and stimulates expression of key en-
zymes involved in thermogenesis and insulin sensitivity in hADSC and pWAT. Naringenin may promote 
conversion of human white adipose tissue to a brown/beige phenotype.
Obesity (2019) 27, 103-111. doi:10.1002/oby.22352
Introduction
Browning of white adipose tissue has garnered interest in research on 
obesity because it engenders adaptive thermogenesis, a process medi-
ated by mitochondrial uncoupling protein 1 (UCP1). When activated, 
UCP1 short-circuits the electrochemical gradient that drives ATP syn-
thesis. Downregulation of the proton gradient stimulates respiratory 
chain activity and provokes heat production through combustion of 
available substrates (1). This type of metabolically active and ener-
gy-dissipating tissue offers a potential solution to counteract excessive 
fat accumulation, especially because brown adipose tissue is typically 
low in humans and inversely correlates with BMI (2). The browning 
of adipose tissue may also modulate systemic insulin action through 
nonthermogenic mechanisms such as the secretion of insulin-sensitiz-
ing factors from adipose tissue (1). Thus, the therapeutic potential of 
brown fat transcends obesity and may be considered for other meta-
bolic abnormalities such as insulin resistance.
Carbohydrate-responsive element-binding protein (ChREBP) is a tran-
scription factor that is known to be expressed as α and β alternatively 
spliced isoforms. In humans, expression of both isoforms in white adi-
pose tissue correlates with insulin sensitivity (3-5); however, obesity 
is associated with a specific reduction in ChREBPβ expression (3,5). 
Overexpression of ChREBP in mice fed a Western diet was shown 
to enhance systemic insulin sensitivity, reduce fat mass, and increase 
expression of the genes associated with thermogenesis, suggesting a 
role for ChREBP in whole-body insulin sensitivity and brown adipose 
tissue function (6). To date, the only compound known to stimulate 
ChREBP expression (in mouse adipose tissue) is the incretin mimetic 
liraglutide (7).
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Strategies to enhance adipose tissue glucose uptake and restore 
depleted levels of ChREBP expression can be particularly beneficial 
to individuals with obesity and insulin resistance. Naringenin, a citrus 
flavonoid, reduces diet-induced weight gain, increases energy expen-
diture, and improves glucose and lipid metabolism in animal models 
(8-12). Activation of AMP-activated protein kinase (AMPK), regula-
tion of insulin signaling pathways and lipid metabolism, relief from 
oxidative stress in pancreatic beta cells, and increases in brown fat ther-
mogenic gene expression are among the mechanisms that have been 
implicated (8-11). The effects of naringenin on energy expenditure and 
expression of the genes involved in glucose metabolism in human adi-
pose tissue have not been investigated.
The literature is replete with the beneficial effects of naringenin in obe-
sity, cardiovascular disease, and cancer (13). However, grapefruit has 
been shown to increase the bioavailability of drugs administered orally. 
Several compounds in grapefruit including the flavonoids (naringin and 
naringenin), furanocoumarins, and sesquiterpenes have been impli-
cated (14). Naringenin, being polyphenolic and high in electrons, can 
theoretically inhibit cytochrome P450 enzymes and enhance the bio-
availability of medications including statins. Although inhibition of the 
cytochrome P450 enzyme system has been demonstrated in vitro and 
in rodent models, the results of in vivo studies in humans suggest that 
naringenin is not the main inhibitory compound in grapefruit (15,16). 
The most potent inhibitor of CYP3A4, the main enzyme in the cyto-
chrome P450 family that is involved in drug metabolism, is bergapten, 
a furanocoumarin derivative (17).
We investigated the effects of naringenin on energy expenditure in human 
adipocytes and primary human white adipose tissue. Preliminary studies 
demonstrated that exposure of human adipocytes to naringenin upregulated 
the mRNA expression of UCP1 and glucose transporter type 4 (GLUT4, 
also known as solute carrier family 2 member 4 [SLC2A4]). We therefore 
hypothesized that naringenin acts in white adipose tissue to promote con-
version of human white adipocytes to the beige/brown phenotype.
Methods
Materials
Hyclone DMEM/Ham’s F12 (DMEM/F12 1:1) and Gibco fetal bo-
vine serum (FBS) were purchased from Thermo Fisher Scientific 
(Waltham, Massachusetts). Rosiglitazone was purchased from AK 
Scientific (Union City, California). All other reagents used in the 
medium were purchased from Sigma-Aldrich (St. Louis, Missouri). 
Naringenin (purity ≥ 98%) was purchased from Cayman Chemicals 
(Ann Arbor, Michigan). Protease and phosphatase were purchased 
from Cell Signaling Technology (CST; Danvers, Massachusetts), radio-
immunoprecipitation assay buffer was purchased from Sigma-Aldrich, 
and TGX protein gels were purchased from Bio-Rad (Hercules, 
California). Seahorse XF assay medium and pyruvate solution were 
purchased from Agilent (Santa Clara, California). Carbonyl cya-
nide-4-(trifluoromethoxy) phenylhydrazone (FCCP), oligomycin, and 
antimycin A were purchased from Sigma-Aldrich.
Cell culture (adipocytes)
Human adipose-derived stem cells from female donors with over-
weight or obesity were purchased from LaCell, LLC (New Orleans, 
Louisiana). Preadipocytes were seeded in DMEM/F12 1:1 supple-
mented with 10% FBS and 1% antibiotic (penicillin/streptomycin/
amphotericin). One day after reaching confluence, cells were differ-
entiated (human white adipocyte cultures [hADSC]) in media con-
taining 70% DMEM and 30% DMEM/F12 1:1 supplemented with 3% 
FBS, 1% antibiotic, 1µM dexamethasone, 33µM biotin, 0.1µM insulin, 
20µM pantothenate, 5µM rosiglitazone, and 500µM 3-isobutylmeth-
ylxanthine. After induction in the differentiation media (4 or 5 days), 
cells were maintained in medium composed of 70% DMEM and 30% 
DMEM/F12 1:1 supplemented with 3% FBS, 1μM dexamethasone, 
33μM biotin, 0.1µM insulin, and 20μM pantothenate (day 0). Cells 
were kept at 37°C in a humidified atmosphere of 95% air and 5% CO2. 
Treatments [8µM naringenin based on pharmacokinetic study done 
in humans (18)] started from day 3 were administered every 2 days 
over a period of 6 days, and cells were harvested the following day 
(day 10). Dexamethasone was removed from the maintenance medium 
during treatment to promote browning of adipocytes (19), and FBS 
was inactivated by heating for 30 minutes at 56°C. Following harvest, 
TRIzol reagent (Sigma-Aldrich) was added to lyse adipocytes, and the 
contents of each well were homogenized. RNeasy Mini Kit (Qiagen, 
Germantown, Maryland) was used to isolate RNA following manufac-
turer’s protocol.
Ex vivo adipose tissue explants
Abdominal subcutaneous adipose tissue (pWAT) procured from four 
females, subjects 1, 2, 3, and 4 undergoing elective panniculectomies, 
was mechanically minced into 0.5- to 1-mm diameter segments and 
500 µL was suspended in 3 mL of adipocyte maintenance medium for 
each replicate (day 0). Treatments (8µM naringenin) started from day 
3 were administered to subjects 1, 2, and 3 every 2 days over a period 
of 14 days or were started at day 10 and treated over 7 days. All pWAT 
samples, including those from the untreated controls, were harvested 
on the same day. In a separate experiment, pWAT from subjects 1, 2, 
and 4 was treated in a similar fashion with GW 7647 (0.3µM). At the 
end of the treatment period, adipocytes were isolated from pWAT after 
standard collagenase digestion, and RNA was extracted with TRIzol. 
Subject characteristics are provided in Table 1.
Quantitative real-time polymerase chain reaction
The RNA was quantified using Invitrogen Qubit RNA Broad-Range 
Assay Kit and read using a Qubit Fluorometer (Thermo Fisher 
Scientific). Reverse transcriptase and real-time polymerase chain 
reaction (RT-PCR) were conducted in one reaction with the reverse 
PCR primer priming complementary DNA (cDNA) synthesis using 
SuperScript III Platinum One-Step qRT-PCR Kit with ROX from 
Invitrogen (Thermo Fisher Scientific). Amplicons were designed 
to span intron-exon junctions to avoid amplification of genomic se-
quences. Primer and probe oligonucleotide sets were purchased from 
Integrated DNA Technologies (Coralville, Iowa) and are provided in 
Table 2. RPL13A (TaqMan identifier Hs04194366_g1, Thermo Fisher 
TABLE 1 Characteristics of donors of adipose tissue used in 
explant experiments
Subject Age BMI Race
1 33 29.2 Caucasian
2 45 25.8 Caucasian
3 39 29.3 African American
4 35 26.1 African American
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Scientific) was used as a housekeeping gene. The RT-PCR assay for 
each sample was conducted in duplicate using the protocol for Applied 
Biosystems (7900 HT, Thermo Fisher Scientific), with the exception 
that an extension temperature of 61°C was used in the assay to measure 
ChREBPβ.
Western blots
Cells from three donors treated with 10µM naringenin for 6 days or 
untreated controls were lysed in radioimmunoprecipitation assay buf-
fer containing a mixture of protease and phosphatase. TGX sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels 
(Any kD, Bio-Rad) were used to separate 50 µg of solubilized protein 
per sample. Following transfer, nitrocellulose membranes were probed 
overnight at 4°C with primary antibodies against UCP1 (#MAB6158, 
R&D Systems), GLUT4 (#sc-53566, Santa Cruz), ChREBP (#sc515922, 
Santa Cruz), AMPK (#2535S, CST), phosphorylated AMPK (T-172, 
#2532S, CST), and β-actin (A5316, Sigma). Horseradish peroxidase–
linked anti-rabbit (12-348, Sigma) and anti-mouse (AP130P, Sigma) 
antibodies were used to detect specific antibody-antigen complexes. 
Proteins were visualized by chemiluminescence (Western Lightning 
Plus-ECL, PerkinElmer, Waltham, Massachusetts). Densitometric 
analyses were performed using ImageJ software (National Institutes of 
Health), and the relative expression of the target protein versus β-actin 
was calculated.
TABLE 2 Primer and probe sequences for qPCR
Gene Primer and probe Sequences
NCBI reference 
sequence
Adiponectin Forward CTGGTGAGAAGGGTGAGAAAG NM_004797.2
Reverse CTCCTTTCCTGCCTTGGATT
Probe TGGTCCTAAGGGAGACATCGGTGA
ATGL Forward CGTGTACTGTGGGCTCATC NM_020376.3
Reverse GGACACTGTGATGGTGTTCTTA
Probe ATGGTGGCATTTCAGACAACCTGC
CPT1B Forward TACCATGGGTGGATGTTTGAG NM_013261.3
Reverse GTCTGGAAGCTGTAGAGCATAG
Probe TCTGGGCTATGTGTATCCGCCTTCTA
ChREBP Forward TCTGGACACAGCCGTCT NM_032951
Reverse GCTTGGGGTCTTCAGGAA
Probe ATCAGAACTCAGGAAGGCGCTGG
ChREBPβ Forward GAGCGGATTCCAGGTGAG BG616809.1
Reverse TTGTTCAGGCGGATCTTGT
Probe TCATCAGTGGCAAGCTGGTGTCTC
GLUT4 Forward GTATCATCTCTCAGTGGCTTGG NM_001042
Reverse ATAGGAGGCAGCAGCATTG
Probe AAAGGGCCATGCTGGTCAACAATG
PGC-1α Forward CACCAAACCCACAGAGAACA NM_00145134.1
Reverse GGGTCAGAGGAAGAGATAAAGTTG
Probe AAAGAAGTCCCACACACAGTCGCA
PGC-1β Forward GAGGCGCTTTGAAGTGTTTG NM_001172699
Reverse GAACACCGGTAGGTGATGAAG
Probe CAGCACCTCGCACTCCTCAATCTC
PRDM16 Forward TCGGAAATCAGAAACTTTATTGCC NM_199454
Reverse TCCTGCTTCTCACTGGCTA
Probe TCTCTGTTCGCGTTGATGCTTGGT
SIRT1 Forward GTTTCATGATAGCAAGCGGTTC NM_001142498
Reverse GTCATGGTTCCTTTGCAACAG
Probe CTCGATGTCCTAGGTGCCCAGC
UCP1 Forward GAGGAGTGGCAGTATTCATTGG NM_021833
Reverse CCGTGTAGCGAGGTTTGATT
Probe TTCAAGCACAGAGCCATCTCCACG
ATGL, adipose triglyceride lipase; ChREBP, carbohydrate-responsive element-binding protein; ChREBPβ, ChREBP beta; CPT1B, carnitine palmitoyltransferase 1B; GLUT4, 
glucose transporter type 4, PGC-1 α/β, peroxisome proliferator-activated receptor gamma coactivator l alpha/beta; NCBI, National Center for Biotechnology Information; 
PRDM16, PR domain containing 16; qPCR, quantitative polymerase chain reaction; SIRT1, sirtuin 1; UCP1, uncoupling protein 1.
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Mitochondrial bioenergetics
To study mitochondrial bioenergetics in human white adipocytes, a 
Seahorse XF24 Extracellular Flux Analyzer (Agilent) was used. The 
human adipose-derived stem cells were seeded onto the Seahorse 
XF24 V7 plate. The protocol for evaluating the bioenergetics parame-
ters of the adipocytes was previously described (20). Briefly, sequen-
tial injections of oligomycin (2µM) to inhibit ATP synthase, FCCP 
(2µM) to uncouple electron transport and allow for maximum electron 
flux through the electron transport chain, and antimycin A (1.5 µg/mL) 
to inhibit complex III were used to determine oxygen consumption rate 
(OCR). Basal OCR was measured before any injections. The difference 
between basal OCR and respiration that resulted when oligomycin was 
injected reflects ATP-linked OCR. Following FCCP injection, max-
imal OCR was measured, and the difference between this value and 
basal OCR reflects the reserve capacity. Nonmitochondrial OCR was 
measured after injecting antimycin A, and the difference between this 
value and OCR that resulted from inhibition of ATP synthase by oligo-
mycin was the basal proton leak.
Cells were treated every other day over 5 days with 8µM naringenin, 
0.1µM rosiglitazone, or 0.3µM GW 7647 or were untreated controls. 
Prior to the assay on day 6, 625 µL per well serum-free Seahorse 
XF assay media, containing 5mM pyruvate, was loaded onto the 
plates. Plates were equilibrated in a non-CO2 incubator at 37°C for 
20 minutes before obtaining the bioenergetics profiles. Experiments 
included four plates (4-8 replicates) with naringenin, rosiglitazone, 
and control as the treatments, and two plates also included GW 7647 
as a treatment.
Statistical analysis
A general linear model was used to perform analysis of variance 
(ANOVA). The primary outcomes, which were differences from the 
controls, were analyzed after Welch test of homogeneity of vari-
ances. The assumption of normality was assessed using the Shapiro-
Wilk test. For data that were not normally distributed, statistical 
significance was verified by logarithm or square root transforma-
tions or by nonparametric analysis (Wilcoxon rank sum test). For the 
Seahorse data, a general linear model was used to perform ANOVA 
to assess the statistical significance of differences among the four 
treatments (naringenin, rosiglitazone, GW 7647, and control) after 
accounting for statistical variability in the respective outcomes that 
was attributable to plates. Six separate models were analyzed with 
each of the six outcomes (basal, ATP-linked, maximal, reserve, 
proton-linked, and nonmitochondrial OCR) taken in turn as the de-
pendent variable and as a linear function of models containing the 
explanatory variables (treatment, plates nested within treatments, 
and wells nested within plates). The magnitude of the component 
of outcome variance attributable to plates was tested against the 
alternative of being significantly different from zero, and if there 
was strong evidence in favor of the alternative, the mean square 
for plates within treatments was used as a denominator in testing 
for treatment differences. If there was not strong evidence in favor 
of a significant component of variability attributable to plates, the 
mean square for wells within plates was used as a denominator in 
testing for treatment differences. Statistical significance of specific 
pairwise differences between treatments was tested by formulating 
specific contrasts among the four treatments. Significance was set 
at P < 0.05. Outcomes are summarized as mean ± SE. All analyses 
were performed using SAS 9.4 (SAS Institute, Cary, North Carolina).
Results
Naringenin promotes thermogenic gene 
expression in human adipocytes
As shown in Figure 1, naringenin treatment increased mRNA levels 
of UCP1, peroxisome proliferator-activated receptor gamma (PPARγ) 
coactivator (PGC) l alpha (PGC-1α, also known as PPARGC1A), and 
(PPARγ) coactivator l beta (PGC-1β, also known as PPARGC1B). 
PGCs can mediate PPARγ-dependent transcriptional responses and 
are involved in mitochondrial biogenesis and uncoupling. PGC-1α and 
PGC-1β can exhibit different regulation patterns (21). Although the in-
duction of PGC-1α was small (40% over controls), the regulation was 
statistically significant (P = 0.013).
Figure 1 Quantitative real-time polymerase chain reaction (qRT-PCR) in human adipocytes treated with naringenin. qRT-PCR assays for 
mRNA expression conducted in duplicates following naringenin treatment of hADSC for 7 days compared with untreated hADSC (control): 
uncoupling protein 1 (UCP1, n = 26), adipose triglyceride lipase (ATGL, n = 12), carnitine palmitoyltransferase 1B (CPT1B, n = 16), glucose 
transporter type 4 (GLUT4, n = 16), carbohydrate-responsive element-binding protein α + β (ChREBP, n = 12), ChREBP beta isoform 
(ChREBPβ, n = 12), adiponectin (n = 12), sirtuin 1 (SIRT1, n = 4), PR domain containing 16 (PRDM16, n = 12), and peroxisome proliferator-
activated receptor gamma coactivator 1 alpha/beta (PGC-1α/β, n = 12). Results are presented as mean ± SE. **P < 0.01, compared with 
respective controls. Each experiment was conducted with four samples except for measurement of UCP1 mRNA that had four or six 
samples.
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Fat mobilization in adipose tissue is effected by adipose triglyceride 
lipase (ATGL) (22). We observed that ATGL (also known as patatin like 
phospholipase domain containing 2 [PNPLA2]) mRNA increased with 
naringenin treatment. Expression of the gene encoding carnitine palmi-
toyltransferase 1B, which transports fatty acids into the mitochondria, 
was increased by 55% over controls, but this regulation was statisti-
cally significant (P < 0.01). The mRNA expression of genes associated 
with insulin sensitivity, GLUT4, ChREBP (also known as MLX inter-
acting protein like [MLXIPL]) (which reflects α + β), ChREBPβ, and 
adiponectin, increased in the naringenin-treated adipocytes (P < 0.01). 
Although sirtuin 1 activity increases the thermogenic capacity of white 
adipose tissue by mediating PR domain containing 16-driven activation 
of thermogenesis (23), we did not observe any changes in the mRNA 
expression of sirtuin 1 or PR domain containing 16 (Figure 1).
Chronic AMPK activation is involved in the remodeling of adipose 
tissue through upregulation of pathways that favor energy dissipation 
(24). In hADSC, naringenin treatment increased protein expression of 
UCP1 (3-day: P < 0.01, 7-day: P = 0.01), GLUT4 (3-day and 7-day: 
P = 0.02), and ChREBP (7-day: P = 0.02) and phosphorylation of 
AMPK (7-day: P = 0.02) (Figure 2).
In primary adipose tissue, response to naringenin 
varies among subjects
To more closely model the response of adult white adipose tissue 
in vivo, pWAT was maintained in organ culture with exposure to 
vehicle or naringenin for 7 or 14 days. There were marked dif-
ferences in the response to naringenin treatment in the adipose 
Figure 2 Immunoblotting in human adipocytes treated with naringenin. Human adipocytes 
from three donors were treated with naringenin for 3 or 7 days. (A) Cellular protein was 
extracted, and Western blot analysis was used to detect protein levels of uncoupling protein 
1 (UCP1), glucose transporter type 4 (GLUT4), and carbohydrate-responsive element-binding 
protein (ChREBP) and phosphorylation levels of AMP-activated protein kinase (AMPK) 
in the untreated controls (C) after 3 days (3d) and 7 days (7d) of naringenin treatment. (B) 
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Figure 3 Quantitative real-time polymerase chain reaction (qRT-PCR) in primary human adipose tissue treated with naringenin. qRT-PCR assays for 
mRNA expression conducted in duplicates following naringenin treatment of quadruplicate pWAT samples, from three female donors with overweight, 
for 7 and 14 days compared with untreated pWAT (control): (A) uncoupling protein 1 (UCP1), (B) adipose triglyceride lipase (ATGL), (C) peroxisome 
proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), (D) peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC-1β), 
(E) glucose transporter type 4 (GLUT4), (F) adiponectin, (G) carbohydrate-responsive element-binding protein α + β (ChREBP), and (H) ChREBP beta 
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tissues from the three different subjects. In subject 1, mRNA ex-
pression of UCP1 did not increase. In subject 2, there was a sub-
stantial increase in UCP1, but the variability among the samples 
precluded attainment of statistical significance. However, in 
subject 3, the increase in UCP1 expression was statistically sig-
nificant at both 7 and 14 days (P = 0.008 and P = 0.001, re-
spectively) of naringenin treatment. The expression of GLUT4 
followed a similar pattern (P = 0.03 and P = 0.003 at 7 and 14 days, 
respectively). Although ChREBP is expressed in brown adipose tis-
sue, induction of UCP1 was not accompanied by increased expres-
sion of ChREBPβ in subject 3. ChREBPβ expression increased in 
subjects 1 and 2 (P = 0.002 and P = 0.013, respectively) at 14 days 
of naringenin treatment. In pWAT of subjects 1 and 3, PGC-1α 
increased at days 7 and 14, respectively (P = 0.04 and P = 0.02), 
whereas PGC-1β increased at 14 days in subjects 2 and 3 (P = 0.03 
and P = 0.005, respectively). In pWAT of subjects 1 and 2, ATGL 
increased at days 7 and 14, respectively (P = 0.02 and P = 0.003), 
and adiponectin increased at 14 days in pWAT of subjects 2 and 3 
(P = 0.008 and P = 0.005, respectively) (Figure 3).
In pWAT from three subjects (including subjects 1, 2, and 4), we 
examined the mRNA expression of UCP1 and GLUT4 following 
treatment with the pharmacologic PPARα agonist GW 7647. Similar 
to the naringenin treatment, in pWAT from subject 1, there was no 
increase in the mRNA expression of UCP1 and GLUT4, whereas 
in pWAT from subject 2, there was a significant increase in UCP1 
(P = 0.003 and P = 0.004 at 7 and 14 days, respectively) and a sub-
stantial increase in GLUT4, but this regulation was not statistically 
significant (Figure 4).
Naringenin increases energy expenditure
As shown in Figure 5, naringenin increased basal, ATP-linked, max-
imal, and reserve OCR in intact adipocytes compared with controls 
(P < 0.01). Basal proton-linked OCR and nonmitochondrial OCR were 
not significantly different between vehicle and treatment groups. ATP-
linked, maximal, reserve, and proton-linked respiration in human ad-
ipocytes exposed to naringenin was similar to those of the positive 
controls, rosiglitazone, and GW 7647 (P > 0.05).
Discussion
Pharmacologic browning of fat correlates with resistance to high-fat 
diet–induced obesity and insulin resistance. In our study, we demon-
strated an increase in the mRNA and protein expression of UCP1, 
GLUT4, and ChREBP, the genes involved in thermogenesis and insu-
lin sensitivity, when hADSC were treated with naringenin at concen-
trations that are physiologically attainable in humans (18). Naringenin 
also stimulated mRNA expression of PGC-1α and PGC-1β (nuclear 
receptor coactivators involved in thermogenesis), ATGL and carnitine 
palmitoyltransferase 1B  (key enzymes necessary for fat oxidation), 
and adiponectin (insulin-sensitizing adipokine), in addition to increas-
ing OCR.
In pWAT maintained ex vivo, the response was varied among the adi-
pose tissue obtained from three female subjects with overweight. UCP1 
and GLUT4 expression significantly increased in one of the three 
subjects, which was accompanied by an increase in the expression of 
PGC-1α and PGC-1β. However, expression of ChREBP and ChREBPβ 
increased in pWAT of the subjects who did not manifest an increase 
in UCP1 and GLUT4. Interestingly, the lack of any change in UCP1 
and GLUT4 expression in response to naringenin treatment in pWAT 
of subject 1 was also seen when this pWAT was treated with GW 7647, 
a potent pharmacologic PPARα agonist. In human adipocytes, PPARα 
has been shown to upregulate the expression of the genes involved in 
lipid metabolism and increase maximal OCR (25). Because naringenin 
activates PPARα (10), it is likely that PPARα plays an important role 
in the thermogenic effect of naringenin, but some humans may not be 
responders to this pathway. However, the notion bears investigation 
with larger sample sizes.
Browning of human adipocytes is induced by pharmacologic PPARα 
and γ agonists, GW 7647 and rosiglitazone, respectively, through acti-
vation of a comprehensive gene program that leads to increased mito-
chondrial function and energy consumption (19,26,27). Naringenin is 
an activator of PPARα and γ (10). In mice, naringenin has been shown 
to increase energy expenditure, upregulate UCP1 in brown fat, and 
promote the induction of fat oxidation (12,28). Our in vitro studies in 
human adipocytes suggest that naringenin may induce a browning of 
Figure 4 Quantitative real-time polymerase chain reaction (qRT-PCR) in primary human adipose tissue treated with GW 7647. qRT-PCR assays for mRNA 
expression conducted in duplicates following GW 7647 (pharmacologic peroxisome proliferator-activated receptor alpha agonist) treatment of quadruplicate 
pWAT samples, from three female donors with overweight, for 7 and 14 days compared with untreated pWAT (control): (A) uncoupling protein 1 (UCP1) and (B) 
glucose transporter type 4 (GLUT4). Results are presented as mean ± SE. **P < 0.01, compared with respective controls.
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human white adipose tissue through an upregulation of UCP1 (Figures 
1 and 2) and an increase in OCR (Figure 5). Additionally, the expres-
sion of the PPARγ coactivators PGC-1α and β was stimulated in human 
adipocytes and pWAT. Both members of the PGC1 family are important 
for mitochondrial oxidative metabolism, although differences in their 
interactions with other transcription factors mediate differences in their 
functional specificity (29).
The relevance of increased energy consumption induced by browning to 
human physiology may be debatable, but its effects on glucose metab-
olism have physiologic significance. In humans, approximately 70 mL 
of brown fat can clear 20 to 25 g of glucose from circulation in 24 hours 
(30). Our in vitro studies in human adipocytes clearly demonstrate that 
naringenin increases expression of ChREBP, ChREBPβ, and GLUT4. 
In white adipose tissue, the transcriptional targets of ChREBP include 
the genes involved in adipocyte differentiation, lipid metabolism, and 
browning (6). Mice with adipose-specific GLUT4 overexpression have 
displayed improved glucose control and upregulation of ChREBP 
expression (4). In humans grouped according to their 2-hour blood glu-
cose concentrations, the expression of GLUT4 and ChREBP measured 
in subcutaneous fat biopsies decreased as blood glucose concentrations 
rose across the groups (5). Interestingly, expression of adipose ChREBP 
correlated positively with expression of GLUT4 and insulin sensitivity 
(5). Although the study was done in adolescents with obesity, it pro-
vides preliminary evidence that in humans, ChREBP, ChREBPβ, and 
GLUT4 gene expression correlates with physiologic outcomes related 
to glucose homeostasis. Secretion of adipokines such as adiponectin is 
another key role of adipose tissue that contributes to whole-body insulin 
sensitivity (31). Thiazolidinediones are PPARγ agonists that increase 
insulin sensitivity at least in part through an increase in adiponectin 
secretion (32). In the promoter region of the human adiponectin gene, 
a PPAR-responsive element has been identified and is thought to be the 
mechanism by which thiazolidinediones increase plasma adiponectin 
(33). In our study, naringenin treatment increased adiponectin mRNA 
expression, suggesting a role for naringenin in protecting against insu-
lin resistance.
Shortage of cellular energy stores marked by an increase in AMP 
levels and a decline in ATP levels activates AMPK, which then initi-
ates cellular programs that increase catabolism, mostly by enhancing 
oxidative metabolism and mitochondrial biogenesis (34). Activation 
of AMPK increases UCP1 and induces an accumulation of brown 
adipocytes in murine white adipose tissue (35). Naringenin promotes 
glucose homeostasis in animal models through activation of AMPK 
signaling in the liver, skeletal muscle, and macrophages differenti-
ated from the human cell line THP-1 (36). In our study, activation of 
AMPK was stimulated in human adipocytes treated with naringenin 
(Figure 2). Consistent with the activation of AMPK and increase 
in catabolism, our studies show that naringenin increases mRNA 
expression of ATGL in hADSC and pWAT. Catabolism of fatty acids 
from triglyceride stores is the function of lipolytic enzymes, particu-
larly ATGL, which catalyzes the initial step in triglyceride hydrolysis 
(22).
The distinctive function of brown adipocytes is thermogenic 
energy expenditure, propelled by the catabolic breakdown of lipids. 
Figure 5 Oxygen consumption rate (OCR) in human adipocytes treated with naringenin. OCR was 
measured in mature human adipocytes that were grown in four Seahorse XF24 V7 plates. Cells 
were treated for 6 days with naringenin, rosiglitazone, or GW 7647 or were untreated controls. 
Measurements include basal OCR, ATP-linked OCR after inhibition of ATP synthase by oligomycin, 
maximal respiratory rate, and reserve capacity after artificial uncoupling by carbonyl cyanide-4-
(trifluoromethoxy) phenylhydrazone; nonmitochondrial respiration after inhibition of complex III by 
antimycin A; and proton-linked OCR. Basal, ATP-linked, maximal, and reserve OCR were significantly 
different between the naringenin-treated cells and the untreated controls. ATP-linked, maximal, 
reserve, and proton-linked OCR were not significantly different (P > 0.05) between naringenin and 
the positive controls rosiglitazone and GW 7647. Results are presented as mean ± SE. **P < 0.01, 
compared with control.
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Therefore, to distinguish between white adipocytes and those that 
have potentially acquired a brown/beige phenotype, we extended 
our characterization to the mitochondrial function of naringen-
in-treated adipocytes by analyzing OCR. Basal OCR and ATP-linked 
OCR were higher in the naringenin-treated cells compared with the 
control or untreated cells. To functionally determine browning in 
hADSC, higher substrate oxidation capacity than controls must be 
demonstrated as would be reflected by substantial increases in max-
imal respiration rate. Following sequential injection of compounds 
that modulate mitochondrial function, naringenin increased maxi-
mal respiratory capacity, and this increase was not different from 
that of the positive controls rosiglitazone and GW 7647. However, 
induction of UCP1 following treatment with naringenin is by far 
lower than UCP1 induction by rosiglitazone in the adipocytes (37). 
Therefore, the increase in energy expenditure may not be com-
pletely mediated by UCP1. Proton leak was not significantly differ-
ent between naringenin and controls. UCP1 is not inherently active 
in the mitochondria and is activated by fatty acids. In intact cells, 
proton leak represents basal uncoupled respiration. In rodent adipocytes, 
injecting isoproterenol during the OCR measurement stimulates an 
adrenergic response, and UCP1-mediated proton leak can be deter-
mined (38). However, in human adipocytes from individuals with 
obesity, the response to β-adrenergic stimulation by isoproterenol is 
impaired (39).
Conclusion
Robust data from rodent studies and in vitro models demonstrate that 
naringenin increases energy expenditure and improves glucose metab-
olism. Although our study in hADSC and pWAT builds upon these 
data, it demonstrates that the response to naringenin may differ among 
human subjects based on their response to pathways that activate en-
ergy expenditure. The results warrant further investigation to deter-
mine their clinical relevance.O
© 2018 The Obesity Society
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